Survival predictors in patients treated with a molecular adsorbent recirculating system

World Journal of Gastroenterology

Volumn 15, Issue 24, 2009, Pages 3015-3024

  Kantola, Taru ^a   Koivusalo, Anna Maria ^a   Parmanen, Satu ^b   Höckertedt, Krister ^c   Isoniemi, Helena ^c  

^a Surgical Hospital   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Acute liver failure; Acute on chronic liver failure; Liver transplantation; Molecular adsorbent recirculating system; Prognostic factors

Indexed keywords

ALANINE AMINOTRANSFERASE; AMMONIA; ANTITHROMBIN III; ASPARTATE AMINOTRANSFERASE; BLOOD CLOTTING FACTOR 5; C REACTIVE PROTEIN; CREATININE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEMOGLOBIN; PARACETAMOL; UREA; VASOACTIVE AGENT;

ACUTE ON CHRONIC LIVER FAILURE; ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN DIALYSIS; AMMONIA BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD PRESSURE; BRAIN DISEASE; CLINICAL TRIAL; CONSCIOUSNESS LEVEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GRAFT FAILURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTENSIVE CARE UNIT; INTERNATIONAL NORMALIZED RATIO; LEUKOCYTE COUNT; LIVER DYSFUNCTION; LIVER FAILURE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; POSTOPERATIVE COMPLICATION; SURVIVAL RATE; THROMBIN TIME; THROMBOCYTE COUNT; UREA BLOOD LEVEL; URINE VOLUME; VENTILATOR;

EID: 67651242225     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.3015     Document Type: Article

References (63)

1. Stange J, Mitzner S, Ramlow W, Gliesche T, Hickstein H, Schmidt R. A new procedure for the removal of protein bound drugs and toxins. ASAIO J 1993; 39: M621-M625
2. Stange J, Mitzner S. A carrier-mediated transport of toxins in a hybrid membrane. Safety barrier between a patients blood and a bioartificial liver. Int J Artif Organs 1996; 19: 677-691
3. Hassanein TI, Tofteng F, Brown RS Jr, McGuire B, Lynch P, Mehta R, Larsen FS, Gornbein J, Stange J, Blei AT. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 2007; 46: 1853-1862
4. Stadlbauer V, Krisper P, Aigner R, Haditsch B, Jung A, Lackner C, Stauber RE. Effect of extracorporeal liver support by MARS and Prometheus on serum cytokines in acute-on-chronic liver failure. Crit Care 2006; 10: R169
5. El Banayosy A, Kizner L, Schueler V, Bergmeier S, Cobaugh D, Koerfer R. First use of the Molecular Adsorbent Recirculating System technique on patients with hypoxic liver failure after cardiogenic shock. ASAIO J 2004; 50: 332-337
6. Heemann U, Treichel U, Loock J, Philipp T, Gerken G, Malago M, Klammt S, Loehr M, Liebe S, Mitzner S, Schmidt R, Stange J. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002; 36: 949-958
7. Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, Berger ED, Lauchart W, Peszynski P, Freytag J, Hickstein H, Loock J, Lohr JM, Liebe S, Emmrich J, Korten G, Schmidt R. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000; 6: 277-286
8. Sen S, Davies NA, Mookerjee RP, Cheshire LM, Hodges SJ, Williams R, Jalan R. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study. Liver Transpl 2004; 10: 1109-1119
9. Saliba F, Camus C, Durand F, Mathurin P, Delafosse B, Barange K, Belnard M, Letierce A, Ichai P, Samuel D. Randomized controlled multicenter trial evaluating the efficacy and safety of albumin dialysis with MARS in patients with fulminant and subfulminant hepatic failure. The liver meeting 2008, 50th anniversary meeting of the international association for the study of liver. San Francisco 2008. Hepatology 2008; 48: 4 suppl
10. Garcia G, Keeffe E. Acute liver failure. In: Friedman LS, Keeffe EB, editors. Handbook of liver disease. New York: Churchill Livingstone, 1998: 15-26
11. Sen S, Williams R, Jalan R. The pathophysiological basis of acute-on-chronic liver failure. Liver 2002; 22 Suppl 2: 5-13
12. Conn HO, Leevy CM, Vlahcevic ZR, Rodgers JB, Maddrey WC, Seeff L, Levy LL. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 1977; 72: 573-583
13. Wellington K, Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs 2001; 15: 465-489
14. Lahdenpera A, Koivusalo AM, Vakkuri A, Hockerstedt K, Isoniemi H. Value of albumin dialysis therapy in severe liver insufficiency. Transpl Int 2005; 17: 717-723
15. United Network for Organ Sharing (UNOS). MELD/PELD calculators, 2008. Available from: URL: http://www.unos.org/resources/ meldpeldcalculator.asp?index=98
16. Freeman RB Jr, Wiesner RH, Roberts JP, McDiarmid S, Dykstra DM, Merion RM. Improving liver allocation: MELD and PELD. Am J Transplant 2004; 4 Suppl 9: 114-131
17. Kremers WK, van IJperen M, Kim WR, Freeman RB, Harper AM, Kamath PS, Wiesner RH. MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients. Hepatology 2004; 39: 764-769
18. Kantola T, Koivusalo AM, Hockerstedt K, Isoniemi H. The effect of molecular adsorbent recirculating system treatment on survival, native liver recovery, and need for liver transplantation in acute liver failure patients. Transpl Int 2008; 21: 857-866
19. Mitzner SR, Klammt S, Peszynski P, Hickstein H, Korten G, Stange J, Schmidt R. Improvement of multiple organ functions in hepatorenal syndrome during albumin dialysis with the molecular adsorbent recirculating system. Ther Apher 2001; 5: 417-422
20. Novelli G, Rossi M, Pretagostini R, Poli L, Peritore D, Berloco P, Di Nicuolo A, Iappelli M, Cortesini R. Use of MARS in the treatment of acute liver failure: preliminar monocentric experience. Transplant Proc 2001; 33: 1942-1944
21. Schmidt LE, Svendsen LB, Sorensen VR, Hansen BA, Larsen FS. Cerebral blood flow velocity increases during a single treatment with the molecular adsorbents recirculating system in patients with acute on chronic liver failure. Liver Transpl 2001; 7: 709-712
22. Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, Berger ED, Lauchart W, Peszynski P, Freytag J, Hickstein H, Loock J, Lohr JM, Liebe S, Emmrich J, Korten G, Schmidt R. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000; 6: 277-286
23. Stange J, Mitzner SR, Klammt S, Freytag J, Peszynski P, Loock J, Hickstein H, Korten G, Schmidt R, Hentschel J, Schulz M, Lohr M, Liebe S, Schareck W, Hopt UT. Liver support by extracorporeal blood purification: a clinical observation. Liver Transpl 2000; 6: 603-613
24. Stange J, Mitzner SR, Risler T, Erley CM, Lauchart W, Goehl H, Klammt S, Peszynski P, Freytag J, Hickstein H, Lohr M, Liebe S, Schareck W, Hopt UT, Schmidt R. Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support. Artif Organs 1999; 23: 319-330
25. Di Campli C, Zileri Dal Verme L, Andrisani MC, Armuzzi A, Candelli M, Gaspari R, Gasbarrini A. Advances in extracorporeal detoxification by MARS dialysis in patients with liver failure. Curr Med Chem 2003; 10: 341-348
26. Jalan R, Sen S, Steiner C, Kapoor D, Alisa A, Williams R. Extracorporeal liver support with molecular adsorbents recirculating system in patients with severe acute alcoholic hepatitis. J Hepatol 2003; 38: 24-31
27. Steiner C, Mitzner S. Experiences with MARS liver support therapy in liver failure: analysis of 176 patients of the International MARS Registry. Liver 2002; 22 Suppl 2: 20-25
28. Wai CT, Lim SG, Aung MO, Lee YM, Sutedja DS, Dan YY, Aw MM, Quak SH, Lee MK, Da Costa M, Prahbakaran K, Lee KH. MARS: a futile tool in centres without active liver transplant support. Liver Int 2007; 27: 69-75
29. Tan HK. Molecular adsorbent recirculating system (MARS). Ann Acad Med Singapore 2004; 33: 329-335
30. Sen S, Mookerjee RP, Davies NA, Williams R, Jalan R. Review article: the molecular adsorbents recirculating system (MARS) in liver failure. Aliment Pharmacol Ther 2002; 16 Suppl 5: 32-38
31. Khuroo MS, Khuroo MS, Farahat KL. Molecular adsorbent recirculating system for acute and acute-on-chronic liver failure: a meta-analysis. Liver Transpl 2004; 10: 1099-1106
32. Wolff B, Machill K, Schumacher D, Schulzki I. MARS dialysis in decompensated alcoholic liver disease: a single-center experience. Liver Transpl 2007; 13: 1189-1192
33. The European Liver and Intestinal Transplant Association (ELITA). European liver transplant registry (eltr) 2008. Available from: URL: http://www.eltr.org/publi/results.php3?id_rubrique=44
34. Scandiatransplant. Scandiatransplant - a nordic organ exchange organization 2007. Available from: URL: http://www.scandiatransplant.org/
35. Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 2004; 10: 1018-1023
36. Farmer DG, Anselmo DM, Ghobrial RM, Yersiz H, McDiarmid SV, Cao C, Weaver M, Figueroa J, Khan K, Vargas J, Saab S, Han S, Durazo F, Goldstein L, Holt C, Busuttil RW. Liver transplantation for fulminant hepatic failure: experience with more than 200 patients over a 17-year period. Ann Surg 2003; 237: 666-675; discussion 675-676
37. Ben Abraham R, Szold O, Merhav H, Biderman P, Kidron A, Nakache R, Oren R, Sorkine P. Rapid resolution of brain edema and improved cerebral perfusion pressure following the molecular adsorbent recycling system in acute liver failure patients. Transplant Proc 2001; 33: 2897-2899
38. Camus C, Lavoue S, Gacouin A, Le Tulzo Y, Lorho R, Boudjema K, Jacquelinet C, Thomas R. Molecular adsorbent recirculating system dialysis in patients with acute liver failure who are assessed for liver transplantation. Intensive Care Med 2006; 32: 1817-1825
39. Felldin M, Friman S, Olausson M, Backman L, Castedal M, Larsson B, Henriksson BA, Siewert-Delle A. [Liver dialysis using MARS in acute hepatic failure. Promising results in a pilot setting] Lakartidningen 2003; 100: 3836-3838, 3841
40. Hassanein T, Oliver D, Stange J, Steiner C. Albumin dialysis in cirrhosis with superimposed acute liver injury: possible impact of albumin dialysis on hospitalization costs. Liver Int 2003; 23 Suppl 3: 61-65
41. Laleman W, Wilmer A, Evenepoel P, Elst IV, Zeegers M, Zaman Z, Verslype C, Fevery J, Nevens F. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care 2006; 10: R108
42. Lee KH, Lee MK, Sutedja DS, Lim SG. Outcome from molecular adsorbent recycling system (MARS) liver dialysis following drug-induced liver failure. Liver Int 2005; 25: 973-977
43. Loock J, Mitzner SR, Peters E, Schmidt R, Stange J. Amino acid dysbalance in liver failure is favourably influenced by recirculating albumin dialysis (MARS). Liver 2002; 22 Suppl 2: 35-39
44. Schmidt LE, Tofteng F, Strauss GI, Larsen FS. Effect of treatment with the Molecular Adsorbents Recirculating System on arterial amino acid levels and cerebral amino acid metabolism in patients with hepatic encephalopathy. Scand J Gastroenterol 2004; 39: 974-980
45. Catalina MV, Barrio J, Anaya F, Salcedo M, Rincon D, Clemente G, Banares R. Hepatic and systemic haemodynamic changes after MARS in patients with acute on chronic liver failure. Liver Int 2003; 23 Suppl 3: 39-43
46. Pugliese F, Novelli G, Poli L, Levi Sandri GB, Di Folco G, Ferretti S, Morabito V, Ruberto F, Berloco PB. Hemodynamic improvement as an additional parameter to evaluate the safety and tolerability of the molecular adsorbent recirculating system in liver failure patients. Transplant Proc 2008; 40: 1925-1928
47. Bernal W, Donaldson N, Wyncoll D, Wendon J. Blood lactate as an early predictor of outcome in paracetamol-induced acute liver failure: a cohort study. Lancet 2002; 359: 558-563
48. Bernuau J, Goudeau A, Poynard T, Dubois F, Lesage G, Yvonnet B, Degott C, Bezeaud A, Rueff B, Benhamou JP. Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology 1986; 6: 648-651
49. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989; 97: 439-445
50. Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg 1964; 1: 1-85
51. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-649
52. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31: 864-871
53. Wiesner RH, McDiarmid SV, Kamath PS, Edwards EB, Malinchoc M, Kremers WK, Krom RA, Kim WR. MELD and PELD: application of survival models to liver allocation. Liver Transpl 2001; 7: 567-580
54. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-470
55. Pereira LM, Langley PG, Hayllar KM, Tredger JM, Williams R. Coagulation factor V and VIII/V ratio as predictors of outcome in paracetamol induced fulminant hepatic failure: relation to other prognostic indicators. Gut 1992; 33: 98-102
56. Brandsaeter B, Hockerstedt K, Friman S, Ericzon BG, Kirkegaard P, Isoniemi H, Olausson M, Broome U, Schmidt L, Foss A, Bjoro K. Fulminant hepatic failure: outcome after listing for highly urgent liver transplantation-12 years experience in the nordic countries. Liver Transpl 2002; 8: 1055-1062
57. Schiodt FV, Lee WM. Liver transplantation for acute liver failure - better safe than sorry. Liver Transpl 2002; 8: 1063-1064
58. Neuberger J. Prediction of survival for patients with fulminant hepatic failure. Hepatology 2005; 41: 19-22
59. Dabos KJ, Newsome PN, Parkinson JA, Davidson JS, Sadler IH, Plevris JN, Hayes PC. A biochemical prognostic model of outcome in paracetamol-induced acute liver injury. Transplantation 2005; 80: 1712-1717
60. Schmidt LE, Dalhoff K. Alpha-fetoprotein is a predictor of outcome in acetaminophen-induced liver injury. Hepatology 2005; 41: 26-31
61. Schiodt FV, Ostapowicz G, Murray N, Satyanarana R, Zaman A, Munoz S, Lee WM. Alpha-fetoprotein and prognosis in acute liver failure. Liver Transpl 2006; 12: 1776-1781
62. Bernal W. Changing patterns of causation and the use of transplantation in the United kingdom. Semin Liver Dis 2003; 23: 227-237
63. Yuan JZ, Ye QF, Zhao LL, Ming YZ, Sun H, Zhu SH, Huang ZF, Wang MM. Preoperative risk factor analysis in orthotopic liver transplantation with pretransplant artificial liver support therapy. World J Gastroenterol 2006; 12: 5055-5059